Company intelligence / Profile preview

Xyphos Biosciences, Inc.

South San Francisco, California, United Statesxyphosinc.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Xyphos’ lead programs are based on its proprietary convertibleCAR™ cell therapy platform. The company’s first product candidates have been in preclinical development with plans for first-in-human studies. No published clinical results as of May 2025[6][10].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Cell therapies (CAR-T cells)Bispecific antibodiesLentiviral vectors
Industry: Biotech

Drug pipeline

1 asset

Convertible CAR-T (lead candidate)

Pre-clinical

Indications: Cancer

Partnerships

Parker Institute for Cancer Immunotherapy[5][6]Phanes Therapeutics[9]VIVEbiotech[9]Kelonia Therapeutics via Astellas partnership[4]

Beyond the preview

Go deeper on Xyphos Biosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xyphos Biosciences, Inc..

Explore the full profile